Serono Onercept Psoriasis Studies Discontinued Due To Safety Concerns
This article was originally published in The Pink Sheet Daily
Serono is discontinuing development of its anti-tumor necrosis factor agent onercept for moderate-to-severe psoriasis based on cases of sepsis reported during Phase III trials, the company said April 6
You may also be interested in...
Serono/CancerVax data safety monitoring board recommends halting Phase III development of Canvaxin for Stage IV melanoma due to lack of efficacy. Pivotal program for Stage III disease continues; no safety issues were identified with either study.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.